Scynexis (SCYX) Cash from Investing Activities Growth (3y) (2016 - 2026)
Powered by 
Analysis
Scynexis (SCYX) Cash from Investing Activities Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -39.19% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -177.73% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 46.78% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 66.14% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -44.69% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -246.81% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -72.08% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -57.11% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -57.11% |
| Sep 30, 2025 | 34.87% |
| Mar 31, 2025 | 1,014.47% |
| Dec 31, 2024 | -64.96% |
| Sep 30, 2024 | 97.83% |
| Jun 30, 2024 | 206.89% |
| Mar 31, 2024 | 208.18% |
| Sep 30, 2023 | -110.87% |
| Jun 30, 2023 | -37.48% |
| Sep 30, 2022 | -302.15% |
| Mar 31, 2022 | -26.02% |
| Dec 31, 2021 | -43.90% |
| Sep 30, 2021 | -26.47% |
| Jun 30, 2021 | 83.95% |
| Mar 31, 2021 | 63.18% |
| Sep 30, 2020 | 6.65% |
| Jun 30, 2020 | 52.28% |
| Mar 31, 2020 | 13.91% |
| Dec 31, 2019 | 21.31% |
| Sep 30, 2019 | 70.01% |